Меню
Идёт набор NCT05008276

Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)

Наблюдательное Type 2 Diabetes Mellitus Diabetic Kidney Disease Adolescent Obesity Pre Diabetes

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Dextran 40.
Кому может быть актуально
Состояния в реестре: Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Adolescent Obesity, Pre Diabetes. Базовые параметры: 8 лет — 14 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

PANTHER Study: Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress

Обзор

Early diabetic kidney disease (DKD) occurs in 50-70% of youth with type 2 diabetes (T2D) and confers high lifetime risk of dialysis and premature death. Youth-onset T2D typically manifests during or shortly after puberty in adolescents with obesity. Epidemiological data implicate puberty as an accelerator of kidney disease in youth with obesity and diabetes and the investigators posit that the link between puberty and T2D-onset may explain the high burden of DKD in youth-onset T2D. A better understanding of the impact of puberty on kidney health is needed to promote preservation of native kidney function, especially in youth with T2D.

Подробное описание

Puberty is a complex process of physiological changes, including neuroreproductive and growth hormone activation and rapid organ growth, that may predispose organs to injury. The kidneys may be especially susceptible because they are highly metabolically active and second only to the heart with respect to oxygen consumption per tissue mass. During puberty, the kidneys almost double in size, likely increasing the kidneys' already high energy expenditure. In parallel, puberty is associated with physiologic insulin resistance (IR), which is accentuated in obesity. Our central hypothesis is that obese youth with prediabetes and T2D experience relative kidney hypoxia during puberty due to a metabolic mismatch between increased energy expenditure and impaired substrate metabolism. In turn, the kidney hypoxia results in loss of glomerular charge and size selectivity leading to increased transglomerular transport of protein and kidney dysfunction. Our preliminary data showed that pubertal adolescents with obesity and/or diabetes exhibit relative kidney hypoxia compared to normal weight controls using functional magnetic resonance imaging (MRI) and that relative kidney hypoxia is greater in late vs. early puberty. However, determining the pubertal mechanisms contributing to kidney injury in youth with obesity and T2D requires serial evaluations throughout puberty. To assess the impact of pubertal changes within a 5-year study period, the investigators propose an accelerated longitudinal study design in which the investigators will enroll adolescents (8-14 years, 50% girls) with obesity and/or elevated hemoglobin A1c (HbA1c ≥6%) \[n=60\], and healthy normoglycemic controls \[n=40\] at Tanner (pubertal) stages 1-4 and examine them at baseline, 1 and 2-years. The investigators will then compare data by Tanner stage to construct an integrated portrayal of the physiological changes that occur throughout puberty. Given the rarity of T2D prior to pubertal onset, the investigators chose to enroll a high high-risk group: youth with obesity and/or HbA1c ≥6.0% to represent youth ranging from those at magnified risk of developing T2D to those recently diagnosed.

Вмешательства

  • Препарат Aminohippurate Sodium Inj 20%
    Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
  • Препарат Iohexol Inj 300 MG/ML
    Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
  • Препарат Dextran 40
    Diagnostic aid/agent used to measure glomerular size and selectivity

Первичные конечные точки

  • Effective renal plasma flow (ERPF) [Срок оценки: 3 Hours]
  • Glomerular Filtration Rate (GFR) [Срок оценки: 3 hours]
Вторичные конечные точки (3)
  • Insulin Sensitivity [Срок оценки: 3 hours]
  • Renal perfusion [Срок оценки: 10 min]
  • Renal oxygenation [Срок оценки: 60 min]

Критерии участия

Критерии включения

  • HbA1c ≥6.0% for untreated high-risk group
  • BMI ≥ 85th %ile for high-risk group
  • Normal HbA1c ≤5.6% for control group
  • Type 1 diabetes (T1D) Antibody negative

Критерии исключения

  • History of Chronic kidney disease (CKD) or acute kidney injury (AKI)
  • Metabolic disorder prohibiting safe fasting
  • Iodine or penicillin allergy
  • Pregnancy
  • Thrombophilia
  • MRI contraindications
  • Hormone therapy

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

США · 2 центра
  • Children's Hospital Colorado — Aurora
  • Seattle Children's Hospital — Seattle

Идентификаторы

NCT: NCT05008276 · 21-3019

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗